


ILLUMINA, INC. NDQ-ILMN

RECENT PRICE **139.49** P/E RATIO **40.4** (Trailing: 45.0 Median: 59.0) RELATIVE P/E RATIO **2.51** DIV'D YLD **Nil** VALUE LINE

TIMELINESS 3 Lowered 12/4/15	High: 8.4 22.9 31.7 47.9 44.1 66.6 79.4 57.0 115.0 197.4 242.4 188.3	Target Price Range 2019 2020 2021
SAFETY 3 Raised 2/27/09	Low: 3.4 6.9 14.1 18.8 23.3 29.8 25.6 28.7 48.0 106.8 130.0 130.4	400 320 200 160 120 100 80 60 40
TECHNICAL 3 Raised 2/12/16	LEGENDS — 40.0 x "Cash Flow" p sh ... Relative Price Strength 2-for-1 split 9/08 Options: Yes Shaded area indicates recession	----- ----- ----- -----
BETA .90 (1.00 = Market)		
2019-21 PROJECTIONS		
Price	Ann'l Total	
High 355 (+155%)	Return 27%	
Low 235 (+70%)	Return 15%	
Insider Decisions		
A M J J A S O N D		
to Buy 0 0 0 0 0 0 0 0 0 0		
Options 6 7 8 7 4 6 4 12 12		
to Sell 12 12 14 13 7 7 2 5 6		
Institutional Decisions		
1Q2015 2Q2015 3Q2015	Percent shares traded	
to Buy 300 292 277	60	
to Sell 226 247 280	40	
Hld's(000) 135517 139806 140044	20	



<p>Illumina, Inc. went public July 28, 2000, through the sale of 6 million shares at \$16 each, in an offering led by Goldman, Sachs, & Co. It uses its <i>BeadArray</i> technology, complemented by its Oligator technology, primarily for SNP (Single Nucleotide Polymorphism) genotyping, a method of analyzing genetic variation in the field of genomics, i.e., the study of the human genome.</p>	<table border="1"> <tr><th></th><th>2006</th><th>2007</th><th>2008</th><th>2009</th><th>2010</th><th>2011</th><th>2012</th><th>2013</th><th>2014</th><th>2015</th><th>2016</th><th>2017</th><th>© VALUE LINE PUB. LLC</th><th>19-21</th></tr> <tr><td>1.97</td><td>3.31</td><td>4.73</td><td>5.58</td><td>7.07</td><td>8.65</td><td>9.27</td><td>11.13</td><td>12.96</td><td>15.10</td><td>17.30</td><td>20.00</td><td></td><td>Sales per sh</td><td>32.90</td></tr> <tr><td>.49</td><td>.54</td><td>.93</td><td>.91</td><td>1.25</td><td>1.17</td><td>1.61</td><td>1.38</td><td>2.89</td><td>3.65</td><td>4.35</td><td>4.55</td><td></td><td>"Cash Flow" per sh</td><td>8.85</td></tr> <tr><td>.41</td><td>.41</td><td>.64</td><td>.61</td><td>.87</td><td>.62</td><td>1.13</td><td>.90</td><td>2.37</td><td>3.10</td><td>3.80</td><td>4.55</td><td></td><td>Earnings per sh ^{AB}</td><td>8.10</td></tr> <tr><td>--</td><td>--</td><td>--</td><td>--</td><td>--</td><td>--</td><td>--</td><td>--</td><td>--</td><td>--</td><td>Nil</td><td>Nil</td><td></td><td>Div'ds Decl'd per sh</td><td>Nil</td></tr> <tr><td>1.16</td><td>.22</td><td>.49</td><td>.43</td><td>.39</td><td>.64</td><td>.56</td><td>.62</td><td>.74</td><td>1.00</td><td>1.10</td><td>1.15</td><td></td><td>Cap'l Spending per sh</td><td>1.25</td></tr> <tr><td>2.64</td><td>3.72</td><td>7.01</td><td>7.23</td><td>9.38</td><td>8.81</td><td>10.64</td><td>12.00</td><td>10.18</td><td>12.60</td><td>17.20</td><td>22.65</td><td></td><td>Book Value per sh ^D</td><td>35.50</td></tr> <tr><td>93.72</td><td>110.79</td><td>121.08</td><td>119.48</td><td>127.63</td><td>122.04</td><td>123.94</td><td>127.72</td><td>143.63</td><td>147.00</td><td>149.00</td><td>150.00</td><td></td><td>Common Shs Outst'g ^C</td><td>155.00</td></tr> <tr><td>37.9</td><td>53.1</td><td>55.9</td><td>56.7</td><td>52.0</td><td>91.5</td><td>40.8</td><td>81.4</td><td>69.6</td><td>62.0</td><td></td><td></td><td></td><td>Avg Ann'l P/E Ratio</td><td>36.5</td></tr> <tr><td>2.05</td><td>2.82</td><td>3.36</td><td>3.78</td><td>3.31</td><td>5.74</td><td>2.60</td><td>4.57</td><td>3.66</td><td>3.15</td><td></td><td></td><td></td><td>Relative P/E Ratio</td><td>2.30</td></tr> <tr><td>--</td><td>--</td><td>--</td><td>--</td><td>--</td><td>--</td><td>--</td><td>--</td><td>--</td><td>--</td><td></td><td></td><td></td><td>Avg Ann'l Div'd Yield</td><td>Nil</td></tr> </table>		2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	© VALUE LINE PUB. LLC	19-21	1.97	3.31	4.73	5.58	7.07	8.65	9.27	11.13	12.96	15.10	17.30	20.00		Sales per sh	32.90	.49	.54	.93	.91	1.25	1.17	1.61	1.38	2.89	3.65	4.35	4.55		"Cash Flow" per sh	8.85	.41	.41	.64	.61	.87	.62	1.13	.90	2.37	3.10	3.80	4.55		Earnings per sh ^{AB}	8.10	--	--	--	--	--	--	--	--	--	--	Nil	Nil		Div'ds Decl'd per sh	Nil	1.16	.22	.49	.43	.39	.64	.56	.62	.74	1.00	1.10	1.15		Cap'l Spending per sh	1.25	2.64	3.72	7.01	7.23	9.38	8.81	10.64	12.00	10.18	12.60	17.20	22.65		Book Value per sh ^D	35.50	93.72	110.79	121.08	119.48	127.63	122.04	123.94	127.72	143.63	147.00	149.00	150.00		Common Shs Outst'g ^C	155.00	37.9	53.1	55.9	56.7	52.0	91.5	40.8	81.4	69.6	62.0				Avg Ann'l P/E Ratio	36.5	2.05	2.82	3.36	3.78	3.31	5.74	2.60	4.57	3.66	3.15				Relative P/E Ratio	2.30	--	--	--	--	--	--	--	--	--	--				Avg Ann'l Div'd Yield	Nil
	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	© VALUE LINE PUB. LLC	19-21																																																																																																																																																								
1.97	3.31	4.73	5.58	7.07	8.65	9.27	11.13	12.96	15.10	17.30	20.00		Sales per sh	32.90																																																																																																																																																								
.49	.54	.93	.91	1.25	1.17	1.61	1.38	2.89	3.65	4.35	4.55		"Cash Flow" per sh	8.85																																																																																																																																																								
.41	.41	.64	.61	.87	.62	1.13	.90	2.37	3.10	3.80	4.55		Earnings per sh ^{AB}	8.10																																																																																																																																																								
--	--	--	--	--	--	--	--	--	--	Nil	Nil		Div'ds Decl'd per sh	Nil																																																																																																																																																								
1.16	.22	.49	.43	.39	.64	.56	.62	.74	1.00	1.10	1.15		Cap'l Spending per sh	1.25																																																																																																																																																								
2.64	3.72	7.01	7.23	9.38	8.81	10.64	12.00	10.18	12.60	17.20	22.65		Book Value per sh ^D	35.50																																																																																																																																																								
93.72	110.79	121.08	119.48	127.63	122.04	123.94	127.72	143.63	147.00	149.00	150.00		Common Shs Outst'g ^C	155.00																																																																																																																																																								
37.9	53.1	55.9	56.7	52.0	91.5	40.8	81.4	69.6	62.0				Avg Ann'l P/E Ratio	36.5																																																																																																																																																								
2.05	2.82	3.36	3.78	3.31	5.74	2.60	4.57	3.66	3.15				Relative P/E Ratio	2.30																																																																																																																																																								
--	--	--	--	--	--	--	--	--	--				Avg Ann'l Div'd Yield	Nil																																																																																																																																																								

<p>CAPITAL STRUCTURE as of 9/27/15 Total Debt \$1110.1 mill. Due in 5 Yrs \$1110.1 mill. LT Debt \$1007.9 mill. LT Interest \$45.0 mill. (34% of Cap'l)</p>	<table border="1"> <tr><td>184.6</td><td>366.8</td><td>573.2</td><td>666.3</td><td>902.7</td><td>1055.5</td><td>1148.5</td><td>1421.2</td><td>1861.4</td><td>2219.7</td><td>2575</td><td>3000</td><td>Sales (\$mill)</td><td>5100</td></tr> <tr><td>23.8%</td><td>19.3%</td><td>25.7%</td><td>25.2%</td><td>27.1%</td><td>29.0%</td><td>27.8%</td><td>23.8%</td><td>35.5%</td><td>37.0%</td><td>36.0%</td><td>38.0%</td><td>Operating Margin</td><td>41.5%</td></tr> <tr><td>6.1</td><td>11.5</td><td>27.7</td><td>24.5</td><td>34.2</td><td>55.6</td><td>48.2</td><td>50.8</td><td>61.9</td><td>72.0</td><td>85.0</td><td>95.0</td><td>Depreciation (\$mill)</td><td>125</td></tr> <tr><td>40.0</td><td>48.5</td><td>84.6</td><td>83.7</td><td>124.9</td><td>86.6</td><td>151.3</td><td>125.3</td><td>353.4</td><td>461.6</td><td>560</td><td>680</td><td>Net Profit (\$mill)</td><td>1250</td></tr> <tr><td>6.2%</td><td>33.7%</td><td>34.9%</td><td>36.7%</td><td>32.6%</td><td>34.9%</td><td>32.1%</td><td>21.3%</td><td>21.3%</td><td>21.5%</td><td>22.5%</td><td>22.5%</td><td>Income Tax Rate</td><td>23.5%</td></tr> <tr><td>21.7%</td><td>13.2%</td><td>14.8%</td><td>12.6%</td><td>13.8%</td><td>8.2%</td><td>13.2%</td><td>8.8%</td><td>19.0%</td><td>20.8%</td><td>23.5%</td><td>22.7%</td><td>Net Profit Margin</td><td>24.6%</td></tr> <tr><td>159.9</td><td>397.1</td><td>355.3</td><td>540.4</td><td>723.9</td><td>1307.0</td><td>1482.5</td><td>1295.4</td><td>1167.7</td><td>1486.2</td><td>1650</td><td>1500</td><td>Working Cap'l (\$mill)</td><td>2100</td></tr> <tr><td>--</td><td>400.0</td><td>--</td><td>--</td><td>--</td><td>807.4</td><td>805.4</td><td>839.3</td><td>986.8</td><td>1015.7</td><td>1000</td><td>1000</td><td>Long-Term Debt (\$mill)</td><td>1100</td></tr> <tr><td>247.3</td><td>411.7</td><td>848.6</td><td>864.2</td><td>1197.7</td><td>1075.2</td><td>1318.6</td><td>1533.2</td><td>1462.8</td><td>1848.6</td><td>2580</td><td>3400</td><td>Shr. Equity (\$mill)</td><td>5500</td></tr> <tr><td>16.2%</td><td>6.2%</td><td>10.1%</td><td>9.8%</td><td>10.5%</td><td>4.6%</td><td>7.1%</td><td>6.1%</td><td>15.2%</td><td>17.0%</td><td>16.5%</td><td>16.0%</td><td>Return on Total Cap'l</td><td>19.5%</td></tr> <tr><td>16.2%</td><td>11.8%</td><td>10.0%</td><td>9.7%</td><td>10.4%</td><td>8.1%</td><td>11.5%</td><td>8.2%</td><td>24.2%</td><td>25.0%</td><td>24.5%</td><td>20.0%</td><td>Return on Shr. Equity</td><td>23.0%</td></tr> <tr><td>16.2%</td><td>11.8%</td><td>10.0%</td><td>9.7%</td><td>10.4%</td><td>8.1%</td><td>11.5%</td><td>8.2%</td><td>24.2%</td><td>25.0%</td><td>24.5%</td><td>20.0%</td><td>Retained to Com Eq</td><td>23.0%</td></tr> <tr><td>--</td><td>--</td><td>--</td><td>--</td><td>--</td><td>--</td><td>--</td><td>--</td><td>--</td><td>--</td><td>Nil</td><td>Nil</td><td>All Div'ds to Net Prof</td><td>Nil</td></tr> </table>	184.6	366.8	573.2	666.3	902.7	1055.5	1148.5	1421.2	1861.4	2219.7	2575	3000	Sales (\$mill)	5100	23.8%	19.3%	25.7%	25.2%	27.1%	29.0%	27.8%	23.8%	35.5%	37.0%	36.0%	38.0%	Operating Margin	41.5%	6.1	11.5	27.7	24.5	34.2	55.6	48.2	50.8	61.9	72.0	85.0	95.0	Depreciation (\$mill)	125	40.0	48.5	84.6	83.7	124.9	86.6	151.3	125.3	353.4	461.6	560	680	Net Profit (\$mill)	1250	6.2%	33.7%	34.9%	36.7%	32.6%	34.9%	32.1%	21.3%	21.3%	21.5%	22.5%	22.5%	Income Tax Rate	23.5%	21.7%	13.2%	14.8%	12.6%	13.8%	8.2%	13.2%	8.8%	19.0%	20.8%	23.5%	22.7%	Net Profit Margin	24.6%	159.9	397.1	355.3	540.4	723.9	1307.0	1482.5	1295.4	1167.7	1486.2	1650	1500	Working Cap'l (\$mill)	2100	--	400.0	--	--	--	807.4	805.4	839.3	986.8	1015.7	1000	1000	Long-Term Debt (\$mill)	1100	247.3	411.7	848.6	864.2	1197.7	1075.2	1318.6	1533.2	1462.8	1848.6	2580	3400	Shr. Equity (\$mill)	5500	16.2%	6.2%	10.1%	9.8%	10.5%	4.6%	7.1%	6.1%	15.2%	17.0%	16.5%	16.0%	Return on Total Cap'l	19.5%	16.2%	11.8%	10.0%	9.7%	10.4%	8.1%	11.5%	8.2%	24.2%	25.0%	24.5%	20.0%	Return on Shr. Equity	23.0%	16.2%	11.8%	10.0%	9.7%	10.4%	8.1%	11.5%	8.2%	24.2%	25.0%	24.5%	20.0%	Retained to Com Eq	23.0%	--	--	--	--	--	--	--	--	--	--	Nil	Nil	All Div'ds to Net Prof	Nil
184.6	366.8	573.2	666.3	902.7	1055.5	1148.5	1421.2	1861.4	2219.7	2575	3000	Sales (\$mill)	5100																																																																																																																																																																										
23.8%	19.3%	25.7%	25.2%	27.1%	29.0%	27.8%	23.8%	35.5%	37.0%	36.0%	38.0%	Operating Margin	41.5%																																																																																																																																																																										
6.1	11.5	27.7	24.5	34.2	55.6	48.2	50.8	61.9	72.0	85.0	95.0	Depreciation (\$mill)	125																																																																																																																																																																										
40.0	48.5	84.6	83.7	124.9	86.6	151.3	125.3	353.4	461.6	560	680	Net Profit (\$mill)	1250																																																																																																																																																																										
6.2%	33.7%	34.9%	36.7%	32.6%	34.9%	32.1%	21.3%	21.3%	21.5%	22.5%	22.5%	Income Tax Rate	23.5%																																																																																																																																																																										
21.7%	13.2%	14.8%	12.6%	13.8%	8.2%	13.2%	8.8%	19.0%	20.8%	23.5%	22.7%	Net Profit Margin	24.6%																																																																																																																																																																										
159.9	397.1	355.3	540.4	723.9	1307.0	1482.5	1295.4	1167.7	1486.2	1650	1500	Working Cap'l (\$mill)	2100																																																																																																																																																																										
--	400.0	--	--	--	807.4	805.4	839.3	986.8	1015.7	1000	1000	Long-Term Debt (\$mill)	1100																																																																																																																																																																										
247.3	411.7	848.6	864.2	1197.7	1075.2	1318.6	1533.2	1462.8	1848.6	2580	3400	Shr. Equity (\$mill)	5500																																																																																																																																																																										
16.2%	6.2%	10.1%	9.8%	10.5%	4.6%	7.1%	6.1%	15.2%	17.0%	16.5%	16.0%	Return on Total Cap'l	19.5%																																																																																																																																																																										
16.2%	11.8%	10.0%	9.7%	10.4%	8.1%	11.5%	8.2%	24.2%	25.0%	24.5%	20.0%	Return on Shr. Equity	23.0%																																																																																																																																																																										
16.2%	11.8%	10.0%	9.7%	10.4%	8.1%	11.5%	8.2%	24.2%	25.0%	24.5%	20.0%	Retained to Com Eq	23.0%																																																																																																																																																																										
--	--	--	--	--	--	--	--	--	--	Nil	Nil	All Div'ds to Net Prof	Nil																																																																																																																																																																										

<p>Leases, Net uncapped: \$32.3 mill. No Defined Benefit Pension Plan</p>	<p>Pfd Stock None</p>	<p>Common Stock 146,400,000 shs. as of 10/8/2015</p>	<p>MARKET CAP: \$20.4 billion (Large Cap)</p>
---	------------------------------	---	--

<p>ANNUAL RATES Past 10 Yrs. 39.0% of change (per sh) Past 5 Yrs. 19.5% Sales Est'd '12-'14 to '19-'21 28.5% "Cash Flow" -- 20.0% Earnings -- 21.5% Dividends -- Nil Book Value 28.0% 13.0% 18.5%</p>	<p>BUSINESS: Illumina, Inc. develops next-generation tools for large-scale analysis of genetic variation and function, for improving drugs and therapies, customizing diagnoses and treatment, and curing disease. Products include its proprietary <i>BeadArray</i> tech., which uses fiber optics to achieve large-scale testing, and its Oligator tech., which synthesizes large quantities of oligonucleotides and short stretches of nucleotides used in genetic analysis. Major shareholders: Baille Gifford, 9.3%; Capital Research, 6.1%; Viking Global, 6.1%; BlackRock, 5.6%. Officers & directors, 2.2% (3/15 proxy). Has more than 3,700 employees. CEO & President: Jay T. Flatley, Inc.: DE. Address: 5200 Illumina Way, San Diego, CA 92122. Telephone: 858-202-4500. Internet: www.illumina.com.</p>
--	---

<p>QUARTERLY SALES (\$ mill.)</p> <table border="1"> <tr><th>Cal-ender</th><th>Mar.Per</th><th>Jun.Per</th><th>Sep.Per</th><th>Dec.Per</th><th>Full Year</th></tr> <tr><td>2013</td><td>331.0</td><td>346.1</td><td>356.8</td><td>387.3</td><td>1421.2</td></tr> <tr><td>2014</td><td>420.8</td><td>447.6</td><td>480.6</td><td>512.4</td><td>1861.4</td></tr> <tr><td>2015</td><td>535.6</td><td>539.4</td><td>553.2</td><td>591.5</td><td>2219.7</td></tr> <tr><td>2016</td><td>625</td><td>620</td><td>635</td><td>695</td><td>2575</td></tr> <tr><td>2017</td><td>730</td><td>725</td><td>750</td><td>795</td><td>3000</td></tr> </table>	Cal-ender	Mar.Per	Jun.Per	Sep.Per	Dec.Per	Full Year	2013	331.0	346.1	356.8	387.3	1421.2	2014	420.8	447.6	480.6	512.4	1861.4	2015	535.6	539.4	553.2	591.5	2219.7	2016	625	620	635	695	2575	2017	730	725	750	795	3000	<p>Shares of Illumina have been hit hard of late. Investors do not react well when a stock that has recently traded with a P/E three times the market average misses earnings and sales marks for successive quarters. In the fourth quarter, the company's revenues increased only 15% due to the strong U.S. dollar. (On a constant-currency basis, the increase was 19%.) The stock is now trading well over 40% from the \$242 high reached in mid-2015. Illumina is also not alone in falling out of favor on Wall Street as investors have currently soured on many high P/E equities.</p>
Cal-ender	Mar.Per	Jun.Per	Sep.Per	Dec.Per	Full Year																																
2013	331.0	346.1	356.8	387.3	1421.2																																
2014	420.8	447.6	480.6	512.4	1861.4																																
2015	535.6	539.4	553.2	591.5	2219.7																																
2016	625	620	635	695	2575																																
2017	730	725	750	795	3000																																

<p>EARNINGS PER SHARE ^{AB}</p> <table border="1"> <tr><th>Cal-ender</th><th>Mar.Per</th><th>Jun.Per</th><th>Sep.Per</th><th>Dec.Per</th><th>Full Year</th></tr> <tr><td>2013</td><td>d.14</td><td>.26</td><td>.22</td><td>.56</td><td>.90</td></tr> <tr><td>2014</td><td>.40</td><td>.31</td><td>.63</td><td>1.03</td><td>2.37</td></tr> <tr><td>2015</td><td>.92</td><td>.69</td><td>.79</td><td>.70</td><td>3.10</td></tr> <tr><td>2016</td><td>1.03</td><td>.82</td><td>.90</td><td>1.05</td><td>3.80</td></tr> <tr><td>2017</td><td>1.20</td><td>1.00</td><td>1.10</td><td>1.25</td><td>4.55</td></tr> </table>	Cal-ender	Mar.Per	Jun.Per	Sep.Per	Dec.Per	Full Year	2013	d.14	.26	.22	.56	.90	2014	.40	.31	.63	1.03	2.37	2015	.92	.69	.79	.70	3.10	2016	1.03	.82	.90	1.05	3.80	2017	1.20	1.00	1.10	1.25	4.55	<p>A promising joint venture has been formed with some prominent people. Management announced the formation of majority-owned GRAIL, a new company that counts Jeff Bezos and Bill Gates among its investors. The goal is to develop a blood-based screening test that will detect cancer at a very early stage. The oncology market is estimated to be a \$20 billion to \$40 billion market, and the payoff down the road could eventually be substantial.</p>
Cal-ender	Mar.Per	Jun.Per	Sep.Per	Dec.Per	Full Year																																
2013	d.14	.26	.22	.56	.90																																
2014	.40	.31	.63	1.03	2.37																																
2015	.92	.69	.79	.70	3.10																																
2016	1.03	.82	.90	1.05	3.80																																
2017	1.20	1.00	1.10	1.25	4.55																																

<p>QUARTERLY DIVIDENDS PAID</p> <table border="1"> <tr><th>Cal-ender</th><th>Mar.31</th><th>Jun.30</th><th>Sep.30</th><th>Dec.31</th><th>Full Year</th></tr> <tr><td>2012</td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>2013</td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>2014</td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>2015</td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>2016</td><td></td><td></td><td></td><td></td><td></td></tr> </table>	Cal-ender	Mar.31	Jun.30	Sep.30	Dec.31	Full Year	2012						2013						2014						2015						2016						<p>Patent, contrarian investors may find these shares of interest. Despite the recent less-than-expected performance, the fundamentals of Illumina have not changed. It remains the dominant force in a high-growth market that is expected to expand rapidly as the cost of sequencing genes continues to decline exponentially. The company manufactures a broad array of machines, is very profitable, is investing heavily in R&D, and has a sound balance sheet. For those investors who have confidence in Illumina, the equity's P/E ratio is now at a low level compared to its historical average.</p>
Cal-ender	Mar.31	Jun.30	Sep.30	Dec.31	Full Year																																
2012																																					
2013																																					
2014																																					
2015																																					
2016																																					

<p>(A) Fiscal year ends on Sunday closest to Dec. 31. Quarter end may not be the last day of the month. (B) Diluted earnings. Excludes non-recurring losses and amortization of intangibles: '07, \$5.96; '08, 31¢; '09, 8¢. GAAP earnings as of 2010. Earnings may not sum due to rounding. Next earnings report due late April. (C) In millions, adjusted for stock split.</p>	<p>(D) Includes intangibles 9/27/15, \$1.043.0 bill./\$7.21 a share.</p>	<p>Company's Financial Strength A Stock's Price Stability 15 Price Growth Persistence 90 Earnings Predictability 55</p>
--	--	---

© 2016 Value Line, Inc. All rights reserved. Factual material is obtained from sources believed to be reliable and is provided without warranties of any kind. THE PUBLISHER IS NOT RESPONSIBLE FOR ANY ERRORS OR OMISSIONS HEREIN. This publication is strictly for subscriber's own, non-commercial, internal use. No part of it may be reproduced, resold, stored or transmitted in any printed, electronic or other form, or used for generating or marketing any printed or electronic publication, service or product.

To subscribe call 1-800-VALUELINE